Advances in pediatric drug for central sedation based on pharmacokinetic/pharmacodynamic modeling and simulation

doi:10.19803/j.1672-8629.2022.07.06

Abstract

Abstract: Objective To summarize the pharmacokinetic/pharmacodynamic (PK/PD) models of central sedative pediatric drugs in order to provide references for quantitative pharmacological models in pediatric drug research and development. Methods The related literature of quantitative pharmacology of central sedative pediatric drugs were collected, analyzed, and summarized in the recent 20 years. Results Clearance was a key parameter to fit the PK/PD models, so it could be critical for determining the doses for pediatrics at different ages. Moreover, there was also a good correlation between the clearance and body weight in pediatric population. Conclusion A close attention should be paid on the physiological characteristics of pediatric patients, especially for investigating drugs acting on the central nervous system. Based on the physiological pharmacokinetic differences and drug exposure-response differences between pediatrics and adults, and considering the practice points of pediatric clinical trials, the PK/PD model supports the pediatric individualized treatment with central sedation drugs.

Key words: pediatric population, pharmacokinetic/pharmacodynamic model, data extrapolation, central sedation, dose regimen, individualized treatment

CLC Number:

R916.62

ZHU Jinying, ZHOU Sufeng, WANG Lu, XU Mingzhe, SHAO Feng. Advances in pediatric drug for central sedation based on pharmacokinetic/pharmacodynamic modeling and simulation[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 721-727.

References

[1] International Council for Harmonisation. E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population[EB/OL].(2018-04-10)[2021-12-30]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11r1-addendum-clinical-investigation-medicinal-products-pediatric-population.
[2] Food and Drug Administration. Best Pharmaceuticals for Children Act (BPCA) [EB/OL]. (2018-09-25)[2021-12-30].https://www.fda.gov/drugs/development-resources/best-pharmaceuticals-children-act-bpca.
[3] Food and Drug Administration. The Pediatric Research Equity Act (PREA) [EB/OL].(2019-11-07)[2022-01-30]. https://www.fda.gov/drugs/development-resources/pediatric-research-equity-act-prea.
[4] SNOWDEN J, DARDEN P, PALUMBO P, et al.The institutional development award states pediatric clinical trials network: building research capacity among the rural and medically underserved[J]. Curr Opin Pediatr, 2018, 30(2): 297-302.
[5] DENG F, LU R, ZHANG H.Effect of exposure to anesthesia on the functions of nervous system of children in the growth period[J]. Medical Journal of Chinese People's Liberation Army(解放军医学杂志), 2015, 40(3): 248-254.
[6] CLARK AJ.General Pharmacology[M]. Berlin: Springer, 1937.
[7] FORBES GB.Body surface as a basis for dosage[J]. Pediatrics, 1959, 23(1): 3-5.
[8] AUGSBERGER A.Old and new rules for dosage determination in paediatrics[J]. Triangle, 1962, 5: 200-207.
[9] LACK JA, STUART-TAYLOR ME.Calculation of drug dosage and body surface area of children[J]. British Journal of Anaesthesia, 1997, 78(5): 601-605.
[10] EMOTO C, FUKUDA T, JOHNSON TN, et al.Development of a pediatric physiologically based pharmacokinetic model for sirolimus: applying principles of growth and maturation in neonates and infants[J]. CPT: Pharmacometrics & Systems Pharmacology, 2015, 4(2): e17.
[11] VINKS AA, EMOTO C, FUKUDA T.Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children[J]. Clinical Pharmacology and Therapeutics, 2015, 98(3): 298-308.
[12] JORGA K, CHAVANNE C, FREY N, et al.Bottom-up meets top-down: complementary physiologically based pharmacokinetic and population pharmacokinetic modeling for regulatory approval of a dosing algorithm of valganciclovir in very young children[J]. Clin Pharmacol Ther, 2016, 100(6): 761-769.
[13] MOULD DR, UPTON RN.Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods[J]. CPT Pharmacometrics Syst Pharmacol, 2013, 2(4): e38.
[14] PETERS SA.Physiologically based pharmacokinetic (PBPK) modeling and simulations[M]. 2nd ed. Hoboken, NJ: John Wiley & Sons, 2021.
[15] Food and Drug Administration. Population pharmacokinetics; guidance for industry[EB/OL].(2022-03-02) [2022-01-30]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/population-pharmacokinetics.
[16] OWEN JS, FIEDLER KJ.Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models[M]. Hoboken, New Jersey: John Wiley & Sons, Inc, 2014.
[17] MAHARAJ AR, EDGINTON AN.Physiologically based pharmacokinetic modeling and simulation in pediatric drug development[J]. CPT Pharma-cometrics Syst Pharmacol, 2014, 3(11): 1-13.
[18] U.S. Food and Drug Administration. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products [EB/OL].(2014-12)[2022-01-30]. https://www.fda.gov/media/90358/download.
[19] YELLEPEDDI V, ROWER J, LIU X, et al.State of the art review on physiologically based pharmacokinetic modeling in pediatric drug development[J]. Clinical pharmacokinetics, 2019, 58(1): 1-13.
[20] BATCHELOR H, APPLETON R, HAWCUTT DB.Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software[J]. Seizure: European Journal of Epilepsy, 2015, 33: 8-12.
[21] VAN RONGEN A, VAUGHNS JD, MOORTHY GS, et al.Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents[J]. British Journal of Clinical Pharmacology, 2015, 80(5): 1185-1196.
[22] VET NJ, BRUSSEE JM, DE HOOG M, et al.Inflammation and organ failure severely affect midazolam clearance in critically ill children[J]. Am J Respir Crit Care Med, 2016, 194(1): 58-66.
[23] BRUSSEE JM, VET NJ, KREKELS EHJ, et al.Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure[J]. British Journal of Clinical Pharmacology, 2018, 84(2): 358-368.
[24] CHIDAMBARAN V, VENKATASUBRAMANIAN R, SADHASIVAM S, et al.Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents[J]. Paediatric anaesthesia, 2015, 25(9): 911-923.
[25] VELLINGA R, HANNIVOORT LN, INTRONA M, et al.Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia[J]. British Journal of Anaesthesia, 2020, 126(2): 386-394.
[26] MICHELET R, VAN BOCXLAER J, ALLEGAERT K, et al.The use of PBPK modeling across the pediatric age range using propofol as a case[J]. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45(6): 765-785.
[27] KOVAR L, SCHRÄPEL C, SELZER D, et al. Physiologically-based pharmacokinetic (PBPK) modeling of buprenorphine in adults, children and preterm neonates[J]. Pharmaceutics, 2020, 12(6): 578.
[28] VAN HOOGDALEM MW, JOHNSON TN, MCPHAIL BT, et al.Physiologically-based pharmacokinetic modeling to investigate the effect of maturation on buprenorphine pharmacokinetics in newborns with neonatal opioid withdrawal syndrome[J]. Clinical Pharmacology and Therapeutics, 2021, 111(2): 496-508.
[29] HAHN D, EMOTO C, EUTENEUER JC, et al.Influence of OCT1 ontogeny and genetic variation on morphine disposition in critically Ill neonates: lessons from PBPK modeling and clinical study[J]. Clinical Pharmacology and Therapeutics, 2019, 105(3): 761-768.
[30] VERSCHEIJDEN LFM, LITJENS CHC, KOENDERINK JB, et al.Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children[J]. PLoS Computational Biology, 2021, 17(3): e1008786-e1008786.
[31] ZHENG L, XU M, TANG SW, et al.Physiologically based pharma-cokinetic modeling of oxycodone in children to support pediatric dosing optimization[J]. Pharmaceutical Research, 2019, 36(12): 171.
[32] MAHARAJ AR, WU H, ZIMMERMAN KO, et al.Population pharmacokinetics of olanzapine in children[J]. Br J Clin Pharmacol, 2021, 87(2): 542-554.
[33] KOVAR L, WEBER A, ZEMLIN M, et al.Physiologically-based pharmacokinetic (PBPK) modeling providing insights into fentanyl pharmacokinetics in adults and pediatric patients[J]. Pharmaceutics, 2020, 12(10): 908.
[34] KE C, YOU X, LIN C, et al.Development of physiologically based pharmacokinetic model for pregabalin to predict the pharmacokinetics in pediatric patients with renal impairment and adjust dosage regimens[J]. Journal of Pharmaceutical Sciences, 2022, 111(2): 542-551.
[35] SINHA J, KARATZA E, GONZALEZ D.Physiologically-based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents[J]. CPT: Pharmacometrics & Systems Pharmacology, 2022, 11(2): 225-239.
[36] MAHARAJ AR, BARRETT JS, EDGINTON AN.A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam[J]. The AAPS Journal, 2013, 15(2): 455-464.
[37] GONZALEZ D, CHAMBERLAIN JM, GUPTILL JT, et al.Population pharmacokinetics and exploratory pharmacodynamics of lorazepam in pediatric status epilepticus[J]. Clinical Pharma-cokinetics, 2017, 56(8): 941-951.
[38] YANG F, TONG X, MCCARVER DG, et al.Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model[J]. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33(4): 485-518.
[39] CSAJKA C, CRETTOL S, GUIDI M, et al.Population genetic-based pharmacokinetic modeling of methadone and its relationship with the QTc interval in opioid-dependent patients[J]. Clinical Pharmacokinetics, 2016, 55(12): 1521-1533.
[40] SCHOEMAKER R, WADE JR, STOCKIS A.Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures[J]. Journal of Clinical Pharmacology, 2016, 56(12): 1591-1602.
[41] MCNAMARA PJ, ALCORN J.Protein binding predictions in infants[J]. AAPS Pharm Sci, 2002, 4(1): 19-26.
[42] EDGINTON AN, SCHMITT W, VOITH B, et al.A mechanistic approach for the scaling of clearance in children[J]. Clinical Pharmacokinetics, 2006, 45(7): 683-704.
[43] HAYTON WL.Maturation and growth of renal function: dosing renally cleared drugs in children[J]. AAPS PharmSci, 2000, 2(1): E3.
[44] WANG JS, DEVANE CL.Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro[J]. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2003, 31(6): 742-747.
[45] SMITH MC, WILLIAMSON J, YASTER M, et al.Off-label use of medications in children undergoing sedation and anesthesia[J]. Anesth Analg, 2012, 115(5): 1148-1154.
[46] BAI JPF, EARP JC, FLORIAN J, et al.Quantitative systems pharmacology: landscape analysis of regulatory submissions to the US Food and Drug Administration[J]. CPT Pharmacometrics Syst Pharmacol, 2021, 10(12): 1479-1484.
[47] AYUSO M, BUYSSENS L, STROE M, et al.The neonatal and juvenile pig in pediatric drug discovery and development[J]. Pharmaceutics, 2020, 13(1): 44.
[48] ENGELHARDT B.Development of the blood-brain barrier[J]. Cell Tissue Res, 2003, 314: 119-129.
[49] VAN DER MAREL CD, ANDERSON BJ, PLUIM MA, et al. Acetaminophen in cerebrospinal fluid in children[J]. Eur J Clin Pharmacol, 2003, 59(4): 297-302.
[50] LI HC, CHEN CC, YEH TY, et al. Predicting hospital mortality and length of stay: a prospective cohort study comparing the intensive care delirium screening checklist versus confusion assessment method for the intensive care unit[J]. Aust Crit Care, 2022, S1036-7314(22): 00011-X.
[51] LU Z, ZHOU N, LI Y, et al.Up-down determination of the 90% effective dose (ED90) of remimazolam besylate for anesthesia induction[J]. Ann Palliat Med, 2022, 11(2): 568-573.
[52] AGRAWAL D, FELDMAN HA, KRAUSS B, et al.Bispectral index monitoring quantifies depth of sedation during emergency department procedural sedation and analgesia in children[J]. Ann Emerg Med, 2004, 43(2): 247-255.
[53] Food and Drug Administration. Model-Informed Drug Develop-ment Pilot Program [EB/OL].(2018-04-16)[2022-01-30].https://www.fda.gov/drugs/development-resources/model-informed-drug-development-pilot-program.
[54] National Medical Products Administration. Technical guidance for pharmacokinetic research in pediatric population[EB/OL].(2014-07-11)[2022-01-30]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20140711112001393.html.
[55] National Medical Products Administration. Technical guidelines for pediatric population drug clinical trials[EB/OL].(2016-03-07)[2022-01-30]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20160307164401912.html.
[56] National Medical Products Administration. Technical guidelines for extrapolating adult medication data to pediatric population[EB/OL].(2017-05-18)[2022-01-30]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20170518163201802.html.
[57] National Medical Products Administration. Technical guidelines for real world research to support drug development and evaluation for children (Trial)[EB/OL].(2020-08-27)[2022-01-30]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200901104448101.html.
[58] Center for Drug Evaluation, National Medical Products Administration. Technical guidelines for clinical pharmacology research of pediatric drugs[EB/OL].(2020-12-31)[2022-01-30]. https://www.cde.org.cn/main/news/viewInfoCommon/eedbe795dfe1d3ab2694c84e786e446e.
[59] Center for Drug Evaluation, National Medical Products Administration. Guiding principles for pharmaceutical development of children's drugs (chemicals)(Trial)[EB/OL].(2020-12-31)[2022-01-30]. https://www.cde.org.cn/main/news/viewInfoCommon/95102a5facaf8fd4430d0916a24eab53.